The purpose of the study is to investigate and compare the human immune response in
epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza
vaccine (LAIV) in adults and in children.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT03023683
Ages eligible for Study
2 Years to 49 Years
Genders eligible for Study
Accepts Healthy Volunteers
Otherwise healthy, ambulatory 2-8 years old (Group A) or 18-49 years old (Group B).
Willing to complete the informed consent process (including assent for minors 7 years old and above).
Availability for follow-up for the planned duration of the study at least 28 days after immunization.
Acceptable medical history by review of inclusion and exclusion criteria and vital signs.
Prior off-study vaccination with the current 2012-2013 seasonal TIV or LAIV.
Allergy to egg or egg products, or to vaccine components, including gentamicin, gelatin, arginine or MSG (LAIV)
Life-threatening reactions to previous influenza vaccinations
Asthma or history of wheezing
Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
History of immunodeficiency (including HIV infection)
Known or suspected impairment of immunologic function, including, but not limited to, clinically significant liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease, or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
Blood pressure >150 systolic or >95 diastolic at the first study visit and on the day of vaccination.
Hospitalization in the past year for congestive heart failure or emphysema.
Chronic Hepatitis B or C.
Recent or current use of immunosuppressive medication, including systemic glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in all groups; inhaled steroid use is not permissible)
Participants in close contact with anyone who has a severely weakened immune system should not receive LAIV
Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia).
Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol.
History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be reviewed by investigator to determine if this would affect the volunteer's safety.
Receipt of blood or blood products within the past 6 months or planned used during the study.
Medical or psychiatric condition or occupational responsibilities that preclude participant compliance with the protocol
Receipt of Inactivated vaccine 14 days prior to study enrollment, or planned vaccinations prior to completion of last visit ( Day ~28 after study vaccination)
Receipt of live, attenuated vaccine within 60 days prior to enrollment of planned vaccination prior to completion of last visit (Day ~28 after study vaccination)
Need for allergy immunization (that cannot be postponed) during the study period.
History of Guillain-Barré syndrome
Pregnant or lactating woman (NA for children in Group A)
Use of investigational agents within 30 days prior to enrollment or planned use during the study.
Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or planned donation prior to completion of the last visit.
A current member of the clinical study team.
Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
All locations for NCT03023683
View full eligibility
Tris trial is registered with FDA with number: NCT03023683. The sponsor of the trial is Stanford University and it is looking for 18 volunteers for the current phase.
Official trial title: U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.